Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorders mediated by various autoantibodies. Although most patients with MG require chronic immunosuppressive treatment to control disease activity, appropriate surveillance biomarkers that monitor disease activity or potential toxicity of immunosuppressants are yet to be developed. Herein, we investigated quantitative distribution of peripheral blood B cell subsets and transcriptional profiles of memory B cells (CD19+ CD27+) in several subgroups of MG patients classified according to the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification. This study suggests potential immunologic B-cell markers that may guide treatment decision in future clinical settings.
Americas ; Autoantibodies ; B-Lymphocyte Subsets ; B-Lymphocytes ; Biomarkers ; Classification ; Flow Cytometry ; Humans ; Immunophenotyping ; Immunosuppressive Agents ; Memory ; Myasthenia Gravis ; Neuromuscular Junction Diseases ; Transcriptome